The FDA has approved Sanofi-Aventis' Taxotere as a combinational therapy for advanced, inoperable head and neck cancer. The approval was based on a Phase III trial that saw the average length of progression-free survival jump to 11.4 months from 8.3 months. "With this approval, I hope to see TPF become the standard of care for induction therapy for patients with this type of cancer," said Marshall Posner, medical director of the head and neck oncology program at Dana-Farber Cancer Institute. Taxotere is already in wide use for a variety of cancers.
- check out the UPI report on the approval